In the VICTORY umbrella trial, second‐line treatment with savolitinib (a highly selective small‐molecule MET inhibitor) resulted in an ORR of 50% in 20 metastatic MET‐amplified GC patients.22 This evidence concerns the gene MET and gastric cancer.